1. A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities

3. Introduction/Overview

4. T2DM as a Risk Factor for CVD

5. Mortality and CVD in T2DM: Data From the Swedish Registry Study

6. Close Linkage Between T2DM and HF

7. T2DM and Patients at CV Risk: Many Targets but Questionable Success

8. A Correlation Exists Between HF and T2DM

9. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

10. SAVOR-TIMI, EXAMINE, TECOS: Topline Results

11. EMPA-REG: Primary Outcome (3-point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

12. EMPA-REG: Results for CV Death

13. Key Outcome of EMPA-REG (but not to be Found in the Published Papers)

14. Potential Mechanisms for CV Benefit Associated With Empagliflozin

15. HF Improvement: Differential Volume Regulation by SGLT2 Inhibitors vs Loop Diuretics

16. The "Fuel Hypothesis" as Explanation of Empagliflozin's Cardiorenal Benefits

17. Glucose and Body Weight Reduction Associated With SGLT2 Inhibitors

18. The Importance of Addressing CVD in the Context of T2DM

19. Kidney Damage and SGLT2 Inhibitors

20. GLP-1 RAs and SGLT2 Inhibitors: Anti-Glycemic Agents or CV Drugs?

21. ELIXA: Primary Outcome: CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for Unstable Angina

22. LEADER: Primary Outcome*

23. LEADER: CV Death

24. SUSTAIN-6 (Semaglutide): Primary Outcome Results

25. LEADER Subgroup Analysis: Effect of Liraglutide on Patients With T2DM and Polyvascular Disease

26. Benefit of Empagliflozin in Patients With HF?

27. Clear-Cut Clinical Roles for Empagliflozin and Liraglutide Based on Different MOAs

28. New Paradigm for Treating the Patient With Both T2DM and CVD

29. Hypothetical Trial: Combination of GLP-1 RA and SGLT2 Inhibitor With CV Endpoints

30. Linkage Between Elevated Glucose and CVD/Events: Correlation or Causality?

31. Pharmacologic Therapy for T2DM: ADA 2018 Recommendations (4)

32. Summary and Conclusions

33. Abbreviations

34. Abbreviations (cont)